Here are the 10-K annual reports from Evolus, Inc. (EOLS) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow EOLS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full EOLS filings page.
Evolus, Inc. is a global performance beauty company focused on cash-pay medical aesthetics, selling the neurotoxin Jeuveau and a line of injectable HA gels branded Evolysse. Jeuveau is approved for frown lines in multiple markets, while Evolysse Form and Smooth were approved in the United States in 2025 for wrinkles and folds.
The company targets growth in large neurotoxin and dermal filler segments but continues to post losses, with a $51.6 million net loss in 2025 and an accumulated deficit of $661.0 million. Evolus depends heavily on manufacturing and licensing partners Daewoong and Symatese, and pays Medytox royalties on Jeuveau sales, which reduces profitability.
Evolus highlights competitive pressures from larger players, regulatory and trade risks, reliance on consumer discretionary spending, and the need for additional financing if assumptions prove incorrect. As of the last reported figures, the company had an approximate market value of $560.4 million and 334 employees across the United States, Canada, Europe and Australia.